+

DE60318466D1 - BINDING COMPOUND TO LEUKOCYTES AND THIS COMPOUND IN MARKED CONDITION AS AN ACTIVE MEDICAL COMPOSITION - Google Patents

BINDING COMPOUND TO LEUKOCYTES AND THIS COMPOUND IN MARKED CONDITION AS AN ACTIVE MEDICAL COMPOSITION

Info

Publication number
DE60318466D1
DE60318466D1 DE60318466T DE60318466T DE60318466D1 DE 60318466 D1 DE60318466 D1 DE 60318466D1 DE 60318466 T DE60318466 T DE 60318466T DE 60318466 T DE60318466 T DE 60318466T DE 60318466 D1 DE60318466 D1 DE 60318466D1
Authority
DE
Germany
Prior art keywords
binding
compound
leukocytes
image diagnosis
monocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318466T
Other languages
German (de)
Other versions
DE60318466T2 (en
Inventor
I Seki
T Kawaguchi
Y Shirakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nihon Medi Physics Co Ltd
Original Assignee
Nihon Medi Physics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Medi Physics Co Ltd filed Critical Nihon Medi Physics Co Ltd
Application granted granted Critical
Publication of DE60318466D1 publication Critical patent/DE60318466D1/en
Publication of DE60318466T2 publication Critical patent/DE60318466T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A compound binding to leukocytes, which comprises Met-Leu-Phe or Nle-Leu-Phe serving as the leukocyte-binding site of a formyl peptide receptor (FPR), a binding part comprising Ser or Thr elevating the binding ratios to monocytes and lymphocytes in all leukocytes, a group which can be labeled with a radioactive metal or a paramagnetic metal, and a spacer binding them shows binding properties specific to all leukocytes, i.e., neutrophils, monocytes and lymphocytes both in vivo and in vitro and can be labeled with a radioactive metal or a paramagnetic metal. Owing to these characteristics, this compound is highly useful in SPECT image diagnosis, PET image diagnosis, MRI image diagnosis and so on wherein imaging is performed in a site with vigorous leukocyte infiltration accompanied by an immune reaction in an individual. <IMAGE>
DE60318466T 2002-09-27 2003-09-26 BINDING COMPOUND TO LEUKOCYTES AND THIS COMPOUND IN MARKED CONDITION AS AN ACTIVE MEDICAL COMPOSITION Expired - Lifetime DE60318466T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002282229 2002-09-27
JP2002282229 2002-09-27
PCT/JP2003/012362 WO2004029080A1 (en) 2002-09-27 2003-09-26 Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient

Publications (2)

Publication Number Publication Date
DE60318466D1 true DE60318466D1 (en) 2008-02-14
DE60318466T2 DE60318466T2 (en) 2008-09-18

Family

ID=32040529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318466T Expired - Lifetime DE60318466T2 (en) 2002-09-27 2003-09-26 BINDING COMPOUND TO LEUKOCYTES AND THIS COMPOUND IN MARKED CONDITION AS AN ACTIVE MEDICAL COMPOSITION

Country Status (16)

Country Link
US (1) US7220827B2 (en)
EP (1) EP1548027B1 (en)
JP (1) JP4279781B2 (en)
KR (1) KR100900178B1 (en)
CN (1) CN1684973A (en)
AT (1) ATE382632T1 (en)
AU (1) AU2003266655B2 (en)
CA (1) CA2498826A1 (en)
DE (1) DE60318466T2 (en)
DK (1) DK1548027T3 (en)
ES (1) ES2297268T3 (en)
IL (1) IL167518A (en)
NO (1) NO20051948L (en)
NZ (1) NZ538869A (en)
TW (1) TW200418880A (en)
WO (1) WO2004029080A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040015234A (en) 2001-05-02 2004-02-18 펄듀 리서치 파운데이션 Treatment and diagnosis of macrophage mediated disease
TWI332404B (en) * 2004-03-25 2010-11-01 Nihon Mediphysics Co Ltd Medicinal composition containing peptide improved in water solubility and metal labeling efficacy thereof and medicinal formulation containing metal labeled peptide
EP1904183B1 (en) * 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
KR100630489B1 (en) 2006-01-10 2006-10-04 주식회사 펩트론 Peptides That Modulate Immune Responses
WO2008098112A2 (en) 2007-02-07 2008-08-14 Purdue Research Foundation Positron emission tomography imaging method
BRPI0813640B1 (en) * 2007-07-11 2023-10-03 The University Of Houston System CONTRAST MARKER AND FABRICATION METHOD OF A FILAMENT
SG181899A1 (en) * 2009-12-23 2012-07-30 Sanford Burnham Med Res Inst Methods and compositions related to annexin 1-binding compounds
JP5994971B2 (en) 2011-03-30 2016-09-21 日本メジフィジックス株式会社 Inflammatory site accumulating compound, nuclear medicine diagnostic imaging agent and labeling precursor
US20220214340A1 (en) * 2019-04-28 2022-07-07 Leide Biosciences Co., Ltd. Zipper structure that helps the formation of protein dimer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4986979A (en) 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
NZ233601A (en) * 1989-05-09 1997-06-24 Gen Hospital Corp N-terminal acylated peptides having an initial sequence met (or nle) -leu-phe and having a detectable label bound through dtpa or edta to a c-terminal lys or pu residue
EP0814849A1 (en) * 1995-10-19 1998-01-07 BRACCO International B.V. Magnetically labeled chemoattractants as targeted contrast agents in the nmr imaging of living tissues
AU4988900A (en) * 1999-05-05 2000-11-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors
WO2001057074A1 (en) * 2000-02-04 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
AU1331802A (en) * 2000-10-17 2002-04-29 Trudeau Inst Inc Cd38 modulated chemotaxis

Also Published As

Publication number Publication date
DE60318466T2 (en) 2008-09-18
ES2297268T3 (en) 2008-05-01
AU2003266655B2 (en) 2009-01-08
JP4279781B2 (en) 2009-06-17
US7220827B2 (en) 2007-05-22
AU2003266655A1 (en) 2004-04-19
TW200418880A (en) 2004-10-01
ATE382632T1 (en) 2008-01-15
KR100900178B1 (en) 2009-06-02
CA2498826A1 (en) 2004-04-08
WO2004029080A1 (en) 2004-04-08
KR20050053691A (en) 2005-06-08
CN1684973A (en) 2005-10-19
EP1548027A1 (en) 2005-06-29
NZ538869A (en) 2006-09-29
IL167518A (en) 2009-11-18
NO20051948L (en) 2005-06-15
US20060057064A1 (en) 2006-03-16
JPWO2004029080A1 (en) 2006-01-26
EP1548027A4 (en) 2005-11-16
DK1548027T3 (en) 2008-05-13
EP1548027B1 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
Signore et al. The molecular imaging approach to image infections and inflammation by nuclear medicine techniques
DE60318466D1 (en) BINDING COMPOUND TO LEUKOCYTES AND THIS COMPOUND IN MARKED CONDITION AS AN ACTIVE MEDICAL COMPOSITION
Mandl et al. Understanding immune cell trafficking patterns via in vivo bioluminescence imaging
Gugliotta et al. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient
Tanimoto et al. Improvement of liver fibrosis by infusion of cultured cells derived from human bone marrow
Mallouk et al. Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies
Hussain et al. Cellular expression of tumour necrosis factor-α and interferon-γ in the liver biopsies of children with chronic liver disease
Pearlman Hepatitis C virus infection in African Americans
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
MX348859B (en) Contrast agents for myocardial perfusion imaging.
SG152254A1 (en) Contrast agents for myocardial perfusion imaging
CN102781316A (en) Cancer diagnosis and imaging
Hong et al. HaloTag: a novel reporter gene for positron emission tomography
Chu et al. Invasive group B Streptococcus isolates showing reduced susceptibility to penicillin in Hong Kong
Corstens et al. Chemotactic peptides: new locomotion for imaging of infection?
DeNardo et al. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice
Kolaczkowska et al. Angiogenic neutrophils: a novel subpopulation paradigm
Shalaby et al. Molecular imaging of cellular immunotherapies in experimental and therapeutic settings
WO2003013346A3 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
Parashurama et al. Multimodality molecular imaging of cardiac cell transplantation: Part I. Reporter gene design, characterization, and optical in vivo imaging of bone marrow stromal cells after myocardial infarction
Laverman et al. Development of infection and inflammation targeting compounds
AASLD et al. Call to action for liver associations to advance progress towards viral hepatitis elimination: a focus on simplified approaches to HCV testing and cure
Signore et al. Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer
Peters Nuclear medicine imaging in infection and inflammation
TW200744645A (en) Contrast agents for myocardium perfusion imaging

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NIHON MEDI-PHYSICS CO., LTD., TOKYO, JP

8364 No opposition during term of opposition
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载